Karyopharm Therapeutics reported $-53448000 in Pre-Tax Profit for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Abbott ABT:US $ 2469M 317M
Abbvie ABBV:US $ 6290M 282M
Acceleron Pharma XLRN:US $ -63.51M 0.05M
Eli Lilly And LLY:US $ 1988.6M 80.6M
Enanta Pharmaceuticals ENTA:US $ -33.41M 4.25M
Epizyme EPZM:US $ -64.36M 5.91M
Five Prime Therapeutics FPRX:US $ -20.85M 0M
GlaxoSmithKline GSK:LN 1482M 225M
Johnson & Johnson JNJ:US $ 7776M 515M
Karyopharm Therapeutics KPTI:US $ -53448000 3.82M
Macrogenics MGNX:US $ -39.94M 11.34M
Nektar Therapeutics NKTR:US $ -125.16M 3.89M
Novartis NOVN:VX SF 4424M 620M
Novartis NVS:US $ 4424M 361M
Regeneron Pharmaceuticals REGN:US $ 3898.3M 2658.7M
Sangamo Biosciences SGMO:US $ -47.15M 1.47M
Tg Therapeutics TGTX:US $ -78.5M 12.13M
Ultragenyx Pharmaceutical RARE:US $ -121.96M 13.8M
Xencor XNCR:US $ 52.25M 54.74M
YTE INCY:US $ 199.6M 31.06M